Home » Topics » Regulatory » EMA

EMA
RSS

CHMP issues positive opinion on Avastin biosimilar ABP-215

Nov. 13, 2017

EMA committee recommends expanding approval of Orkambi

Nov. 13, 2017

EMA's CHMP supports expanding Nplate indication

Nov. 13, 2017

FDA gives orphan status to Achillion's ACH-4471 for PNH

Nov. 8, 2017

Pegfilgrastim biosimilar from Sandoz accepted for EMA review

Oct. 31, 2017

VBL Therapeutics' VB-111 granted orphan medicinal product status in E.U.

Oct. 23, 2017

EMA grants orphan drug designation to G-100 for the treatment of follicular non-Hodgkin's lymphoma

Oct. 20, 2017

EMA grants orphan drug designation to Conatus' IDN-7314 for primary sclerosing cholangitis

Oct. 19, 2017

Ignyta's entrectinib obtains PRIME designation from EMA

Oct. 18, 2017

EMA's CHMP supports expansion of marketing authorization for Zytiga

Oct. 16, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...